Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with or without semaglutide and wearable physical activity feedback after gestational diabetes
ACTRN12624001253594Phase 2Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin and semaglutide in obesity and Overweight (4 arms), sponsored by The George Institute for Global Health. Primary endpoints: Absolute body weight and Mean activity levels. Started Sep 2025; status: recruiting.
02
Drugs
metforminsemaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on ACTRN12624001253594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001253594.